Drug Profile
SP 1049C
Alternative Names: Doxorubicin SP1000 - Supratek Pharma; SP-1049CLatest Information Update: 27 Feb 2023
Price :
$50
*
At a glance
- Originator Supratek Pharma
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Small molecules
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Adenocarcinoma
Most Recent Events
- 27 Feb 2023 Discontinued - Phase-II for Adenocarcinoma in United Kingdom (IV)
- 19 Jan 2011 No development reported - Phase-II for Adenocarcinoma in United Kingdom (IV)
- 28 Nov 2007 US FDA, under a Special Protocol Assessment (SPA), approves the design of phase III study protocol of SP 1049C in metastatic adenocarcinoma of the upper GI